Trulieve Lands First DEA Registrations for Its Dispensaries — But Can Federal Legitimacy Unlock Real Value for a $3 Billion Cannabis Player?

Shares of Trulieve Cannabis surged as much as 10.1% to $11.32 on November 2, after the company announced it had received Drug Enforcement Administration registrations for its medical marijuana dispensaries — a landmark step under the federal government's new framework for recognizing qualifying state-licensed cannabis operators. Trulieve Wins Federal Stamp of Approval From the DEA — But Is the Stock's 10% Pop Just the Beginning or a Sugar High?

Shares of Trulieve Cannabis surged 10.1% to $11.32 after the company announced it had received DEA registrations for its medical marijuana dispensaries — part of the first batch of federal approvals issued to state-licensed operators. The move is historic, but investors should weigh whether the rally reflects a durable shift or simply the latest checkpoint in a long regulatory march.

• The Federal Government Just Told Trulieve Its Business Is Legitimate. Trulieve confirmed on November 2 that it received DEA dispensary registrations as part of the initial issuance that began October 30, following the Attorney General's April order establishing a federal framework for qualifying medical marijuana businesses.

The first phase covers more than 900 dispensaries across seven states, including Florida — Trulieve's home turf. For a company that spent years operating in a legal grey zone, formal federal recognition reduces enforcement risk and opens the door to mainstream banking and institutional capital. Trulieve successfully listed on the New York Stock Exchange earlier this year , and DEA registration reinforces that trajectory.

• The Real Money Is in the Tax Break, Not the Registration Itself. The move to Schedule III in April eliminated Section 280E — a tax rule that blocked cannabis companies from deducting ordinary expenses like rent and payroll, pushing operators like Trulieve to pay tax on something close to gross profit. Schedule III ended that penalty, and the savings flow straight into earnings and cash flow.

Trulieve has confirmed the 280E burden is gone from its medical operations; its Q2 income tax expense included $13 million in ordinary taxes but no 280E liability. That is a structural improvement to every future quarter's bottom line.

• Revenue Is Still Shrinking, and Registration Won't Fix That. Q2 2026 revenue came in at $271 million, down 10.3% year-over-year, with the company operating 206 dispensaries.

Price compression across the domestic cannabis sector shows no definitive signs of stabilization. DEA registration confers legitimacy, not customers. The fundamental challenge — falling prices in a maturing market — persists.

• The Broader Rescheduling Fight Isn't Over. The broader federal marijuana rescheduling proceeding remains separate; cannabis outside the defined medical framework still faces Schedule I restrictions.

Just weeks ago, Trulieve shares fell 14% after a DEA administrative law judge paused the broader rescheduling case following a GAO report flagging gaps. Today's registration is a win for Trulieve's medical business, but adult-use reform — the bigger prize — remains uncertain. At $11.32, the stock prices in progress, not a finish line.